<p>This is a summary of the European public assessment report (EPAR) for Aloxi. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Aloxi.</p>
Therapeutic Indication
<div class="subsection mt-3-5"> <h3>Therapeutic indication</h3><p>Aloxi is indicated in adults for:</p> <ul><li>the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy,</li> <li>the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.</li> </ul><p>Aloxi is indicated in paediatric patients 1 month of age and older for:</p> <ul><li>the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.</li> </ul></div>
Therapeutic Area (MeSH)
ATC Code
A04AA05
ATC Item
N/A
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| palonosetron hydrochloride | N/A | palonosetron hydrochloride |
EMA Name
Aloxi
Medicine Name
Aloxi
Aliases
N/ANo risk management plan link.
